文献速递肿瘤 PET/CT

基线18F-FDG PET/CT影像组学用于弥漫性大B细胞淋巴瘤预后预测

Baseline 18F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma.
PubMed 文献 · EJNMMI Res · 2023-10-26

研究纳入201例弥漫性大B细胞淋巴瘤患者,提取1328个影像组学特征,比较影像组学特征、临床因素和代谢参数对2年无进展生存和5年总生存的预测价值。影像组学特征在无进展生存和总生存上均显示最低AIC值和最高C-index值;影像组学特征与代谢参数在无进展生存的AUC无显著差异,联合模型与影像组学特征单独相比在无进展生存和总生存上均无显著差异。

要点

  • 影像组学特征在无进展生存(AIC 571.688,C-index 0.732)和总生存(AIC 339.843,C-index 0.759)上均优于临床因素和代谢参数。
  • 影像组学特征与临床因素在无进展生存(AUC 0.768 vs 0.681,P=0.017)和总生存(AUC 0.767 vs 0.667,P=0.023)上AUC差异有统计学意义。
  • 影像组学特征与代谢参数在总生存上AUC差异有统计学意义(0.767 vs 0.688,P=0.007),但在无进展生存上无显著差异(0.768 vs 0.756,P=0.654)。

核心结论

  • 源自PET图像的影像组学特征对弥漫性大B细胞淋巴瘤患者的进展显示高预测能力。
  • 影像组学特征、临床因素和代谢参数的联合可能不会显著提高超过影像组学特征单独的预测价值。

研究设计与样本

  • 本研究纳入201例弥漫性大B细胞淋巴瘤患者,提取1328个影像组学特征。
  • 研究比较影像组学特征、临床因素和代谢参数对2年无进展生存和5年总生存的预测价值。

主要发现

  • 影像组学特征、临床因素和代谢参数均显示对弥漫性大B细胞淋巴瘤患者个体化预后预测的显著预后价值。
  • 影像组学特征在无进展生存上AIC为571.688、C-index为0.732,临床因素AIC为596.040、C-index为0.658,代谢参数AIC为576.481、C-index为0.702。
  • 影像组学特征在总生存上AIC为339.843、C-index为0.759,临床因素AIC为363.671、C-index为0.667,代谢参数AIC为358.412、C-index为0.659。
  • 影像组学特征与临床因素AUC比较:无进展生存0.768 vs 0.681(P=0.017),总生存0.767 vs 0.667(P=0.023)。
  • 影像组学特征与代谢参数AUC比较:总生存0.767 vs 0.688(P=0.007),无进展生存0.768 vs 0.756(P=0.654)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in adults. Standard treatment includes chemoimmunotherapy with R-CHOP or similar regimens. Despite treatment advancements, many patients with DLBCL experience refractory disease or relapse. While baseline 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) parameters have shown promise in predicting survival, they may not fully capture lesion heterogeneity. This study aimed to assess the prognostic value of baseline 18F-FDG PET radiomics features in comparison with clinical factors and metabolic parameters for assessing 2-year progression-free survival (PFS) and 5-year overall survival (OS) in patients with DLBCL. RESULTS: A total of 201 patients with DLBCL were enrolled in this study, and 1328 radiomics features were extracted. The radiomics signatures, clinical factors, and metabolic parameters showed significant prognostic value for individualized prognosis prediction in patients with DLBCL. Radiomics signatures showed the lowest Akaike information criterion (AIC) value and highest Harrell's concordance index (C-index) value in comparison with clinical factors and metabolic parameters for both PFS (AIC: 571.688 vs. 596.040 vs. 576.481; C-index: 0.732 vs. 0.658 vs. 0.702, respectively) and OS (AIC: 339.843 vs. 363.671 vs. 358.412; C-index: 0.759 vs. 0.667 vs. 0.659, respectively). Statistically significant differences were observed in the area under the curve (AUC) values between the radiomics signatures and clinical factors for both PFS (AUC: 0.768 vs. 0.681, P = 0.017) and OS (AUC: 0.767 vs. 0.667, P = 0.023). For OS, the AUC of the radiomics signatures were significantly higher than those of metabolic parameters (AUC: 0.767 vs. 0.688, P = 0.007). However, for PFS, no significant difference was observed between the radiomics signatures and metabolic parameters (AUC: 0.768 vs. 0.756, P = 0.654). The combined model and the best-performing individual model (radiomics signatures) alone showed no significant difference for both PFS (AUC: 0.784 vs. 0.768, P = 0.163) or OS (AUC: 0.772 vs. 0.767, P = 0.403). CONCLUSIONS: Radiomics signatures derived from PET images showed the high predictive power for progression in patients with DLBCL. The combination of radiomics signatures, clinical factors, and metabolic parameters may not significantly improve predictive value beyond that of radiomics signatures alone.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Jing F, Liu Y, Zhao X, et al. Baseline 18F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma. EJNMMI Res. 2023. PMID: 37884763. doi:10.1186/s13550-023-01047-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。